To Study the Psychological Impact, Associated Disorders and Treatment Options in Vitiligo
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 发起方
- 入组人数
- 95
- 试验地点
- 1
- 主要终点
- Improved diagnosis and management strategies for healthcare professionals dealing with Vitiligo patients.
研究概览
简要总结
Scope
This thesis will focus on the investigation of clinical and genetic features of vitiligo patients and the evaluation of different treatment modalities, using a combination of cross-sectional and longitudinal study designs. The study will be conducted in the Department of Dermatology, Venereology & Leprosy GMC, Baramulla, and will include patients with different clinical subtypes and severity of vitiligo.
This research focuses on a specific geographic region and aims to provide recent and relevant data regarding the prevalence, psychological impact, associated disorders, and treatment options for Vitiligo.
This research covers recent developments in the study of Vitiligo, encompassing epidemiology, psychological aspects, comorbidities, and emerging treatments. We focus on recent data to ensure the most current understanding of the condition.
Hypotheses
Vitiligo has a negative impact on self-esteem and quality of life.
There is an association between Vitiligo and autoimmune disorders.
Emerging therapies, such as JAK inhibitors, show promise in the treatment of Vitiligo.
Recent epidemiological studies suggest that regions with higher exposure to ultraviolet (UV) radiation have a higher prevalence of Vitiligo.
Recent psychological assessments indicate that individuals with Vitiligo experience lower self-esteem and quality of life compared to those without the condition.
Recent research suggests that support from friends and family, along with professional therapy, positively impacts the psychological well-being of Vitiligo patients.
Recent correlation analyses indicate a strong link between the severity of Vitiligo and the presence of autoimmune co morbidities.
Recent clinical trials highlight the promising potential of emerging therapies like JAK inhibitors in regimenting Vitiligo patches.
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 1.00 Year(s) 至 75.00 Year(s)（—）
- 性别
- Male
入选标准
- •All the patients diagnosed with Vitiligo of all age groups and of either sex visiting OPD of the Dermatology Department and who gave consent during the study period were included in this study.
- •Confirmed vitiligo diagnosis by a healthcare professional through clinical examination, dermoscopy, or biopsy (specific methodology may vary based on study design).
- •Consent to participate in the study procedures, including surveys, interviews, physical examinations, blood tests, or imaging studies (specific procedures depend on study focus).
- •No age or demographic restrictions unless studying specific populations (e.g., pregnant women, above 70 years).
- •Age of consent (e.g., 18+) and ability to complete psychological assessments.
- •Diagnosis of a specific co-occurring disorder confirmed through medical records or additional diagnostic procedures.
- •Specific disease type, severity, and age range suitable for the investigated treatment modality.
排除标准
- •Patients not giving consent to participate in the study.
- •Mimicking Conditions: Presence of skin conditions that could mimic vitiligo (e.g., piebaldism, post-inflammatory hypopigmentation).
- •Self-Reported Vitiligo: Individuals lacking a professional diagnosis of vitiligo.
- •Cognitive/Psychiatric Conditions: Severe cognitive or psychiatric conditions that could significantly impact data collection or interpretation.
- •Medical Conditions: Presence of medical conditions that could confound study results or pose safety risks (e.g., chronic infections, certain medications).
- •Treatment Contraindications: Known contraindications to the specific treatment being investigated (e.g., allergies, specific medical conditions).
- •Ongoing Trials: Participation in other clinical trials that could interfere with study results.
- •Individuals with language barriers that impede effective communication may be excluded.
- •Pregnant or breastfeeding women may be excluded depending on the specific treatment safety data.
- •Uncertain diagnoses of vitiligo or co-occurring disorders may lead to exclusion to ensure study accuracy.
结局指标
主要结局
Improved diagnosis and management strategies for healthcare professionals dealing with Vitiligo patients.
时间窗: 8 weeks
次要结局
- Enhanced psychological support and interventions to address the emotional and social impact of Vitiligo.(6 months)
- Identification of potential Comorbidities and associated disorders to guide comprehensive patient care.(6 months)
- Evaluation of treatment options to determine their effectiveness, patient satisfaction, and areas for improvement.
研究者
Zahid Ashraf
Department of Pharmaceutical Sciences, University of Kashmir